Biotech and NCAV: Why Cash-Rich Pre-Revenue Biotechs Are Mispriced

A biotech company that burns £5m per year and holds £20m in cash is, in a Graham sense, a net-net. Its entire future is funded and its liquidation value exceeds its market cap. Yet most Graham investors ignore biotech entirely, citing the binary risk of clinical trial failure. This is a mistake — cash-rich pre-revenue biotechs represent one of the most analytically tractable net-net niches.

Why Biotech Net-Nets Are Different

Traditional net-nets are cheap because the underlying business is uninspiring or struggling. Biotech net-nets are cheap because of binary risk: the market applies a heavy discount for the probability of trial failure. If you can correctly assess the probability that the cash isn't destroyed before it produces a return, the mispricing can be significant.

The Runway Calculation

The critical variable is runway — how many quarters of cash burn remain before the company needs to raise capital. A biotech with £20m in cash burning £5m annually has four years of runway. Four years is usually enough time for a Phase 2/3 readout. A company with eight months of runway is a dilution event waiting to happen — stay away regardless of the NCAV discount.

What to Look For

Minimum 3 years of cash runway at current burn rate. Published Phase 1 safety data (de-risks binary failure). Licensed or partnered assets that generate milestone payments (reduces burn). Experienced management team with prior exits. The ideal biotech net-net is a small company with a reasonable drug candidate, enough cash, no debt, and a market cap that implies the drug is essentially worthless — because investors are scared of the sector.

AIM-Listed Biotech Net-Nets

AIM is home to a significant number of early-stage biotech companies. Many trade below cash after disappointing Phase 2 results. The key question is: does the remaining pipeline justify the going-concern value? Companies with one failed drug but a second-generation candidate and 3+ years of cash often recover substantially within the window of the holding period. Screen for NCAV ratio, runway, and management ownership.

Biotech investing carries significant risk including total loss of capital. This article is for educational purposes only. Consult a financial adviser before investing in early-stage biotech.